Symbols / BPTH $0.06 +0.00% Bio-Path Holdings, Inc.
BPTH Chart
About
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 560.53K |
| Enterprise Value | — | Income | -8.67M | Sales | — |
| Book/sh | -0.89 | Cash/sh | — | Dividend Yield | — |
| Payout | 0.00% | Employees | 1 | IPO | — |
| P/E | — | Forward P/E | -0.01 | PEG | — |
| P/S | — | P/B | -0.07 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | 0.07 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.14 | EPS next Y | -4.04 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-13 15:00 | ROA | -228.35% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 9.34M |
| Shs Float | 8.85M | Short Float | 1.38% | Short Ratio | 0.43 |
| Short Interest | — | 52W High | 0.23 | 52W Low | 0.05 |
| Beta | -0.33 | Avg Volume | 12.80K | Volume | 10.00K |
| Target Price | — | Recom | None | Prev Close | $0.06 |
| Price | $0.06 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.06
Latest analyst target
3. DCF / Fair value
$4.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.06
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-07-08 | reit | Roth MKM | Buy → Buy | $20 |
| 2024-04-18 | reit | Roth MKM | Buy → Buy | $40 |
| 2024-03-27 | main | Roth MKM | Buy → Buy | $40 |
- [8-K] BIO-PATH HOLDINGS, INC. Reports Material Event - Stock Titan hu, 19 Mar 2026 07
- Bio-Path Holdings announces executive resignations and operational pause - Investing.com ue, 24 Jun 2025 07
- [1-A] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan Wed, 25 Mar 2026 18
- Bio-path Holdings Stock Price Forecast. Should You Buy BPTH? - StockInvest.us ue, 01 Dec 2020 13
- BPTH Stock Price and Chart — OTC:BPTH - TradingView Wed, 19 Feb 2025 13
- All You Need to Know About Bio-Path (BPTH) Rating Upgrade to Buy - Yahoo Finance Wed, 20 Nov 2024 08
- Traders Mystified by 3000% Surge in Shares of Cancer-Drug Maker - Bloomberg.com hu, 07 Mar 2019 08
- Should I buy Bio-Path Holdings (BPTH) - Zacks Investment Research hu, 07 Jul 2016 12
- Bio-Path (BPTH) Stock Price, News & Analysis - MarketBeat Fri, 10 Jul 2015 14
- Bio-Path Holdings to be delisted from Nasdaq - Investing.com ue, 18 Feb 2025 08
- BPTH Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
- Walgreens Layoffs 2024: What to Know About the Latest WBA Job Cuts - InvestorPlace hu, 18 Apr 2024 07
- When Can We Expect A Profit From Bio-Path Holdings, Inc. (NASDAQ:BPTH)? - Yahoo Finance Sat, 17 Feb 2024 08
- Why Bio-Path Holdings (BPTH) Stock Is Down 45% - TradingView hu, 03 Aug 2023 07
- Bio-Path (BPTH) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat Fri, 20 Jun 2025 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
11.99
-24.31%
|
15.84
+13.97%
|
13.90
+33.11%
|
10.44
|
| Research And Development |
|
7.29
-37.16%
|
11.61
+26.66%
|
9.16
+55.08%
|
5.91
|
| Selling General And Administration |
|
4.70
+10.91%
|
4.24
-10.58%
|
4.74
+4.48%
|
4.53
|
| General And Administrative Expense |
|
4.70
+10.91%
|
4.24
-10.58%
|
4.74
+4.48%
|
4.53
|
| Salaries And Wages |
|
—
|
—
|
0.66
+0.00%
|
0.66
|
| Other Gand A |
|
4.70
+10.91%
|
4.24
-10.58%
|
4.74
+4.48%
|
4.53
|
| Total Expenses |
|
11.99
-24.31%
|
15.84
+13.97%
|
13.90
+33.11%
|
10.44
|
| Operating Income |
|
-11.99
+24.31%
|
-15.84
-13.97%
|
-13.90
-33.11%
|
-10.44
|
| Total Operating Income As Reported |
|
-11.99
+24.31%
|
-15.84
-13.97%
|
-13.90
-33.11%
|
-10.44
|
| EBITDA |
|
-11.83
+24.46%
|
-15.66
-14.15%
|
-13.72
-33.47%
|
-10.28
|
| Normalized EBITDA |
|
-13.92
+9.59%
|
-15.39
-12.18%
|
-13.72
-33.47%
|
-10.28
|
| Reconciled Depreciation |
|
0.16
-10.67%
|
0.18
+0.00%
|
0.18
+10.56%
|
0.16
|
| EBIT |
|
-11.99
+24.31%
|
-15.84
-13.97%
|
-13.90
-33.11%
|
-10.44
|
| Total Unusual Items |
|
2.08
+869.00%
|
-0.27
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
2.08
+869.00%
|
-0.27
|
—
|
—
|
| Net Income |
|
-9.89
+38.46%
|
-16.08
-15.94%
|
-13.87
-32.84%
|
-10.44
|
| Pretax Income |
|
-9.89
+38.46%
|
-16.08
-15.94%
|
-13.87
-32.84%
|
-10.44
|
| Net Non Operating Interest Income Expense |
|
0.01
-61.11%
|
0.04
+9.09%
|
0.03
+1000.00%
|
0.00
|
| Net Interest Income |
|
0.01
-61.11%
|
0.04
+9.09%
|
0.03
+1000.00%
|
0.00
|
| Interest Income Non Operating |
|
0.01
-61.11%
|
0.04
+9.09%
|
0.03
+1000.00%
|
0.00
|
| Interest Income |
|
0.01
-61.11%
|
0.04
+9.09%
|
0.03
+1000.00%
|
0.00
|
| Other Income Expense |
|
2.08
+869.00%
|
-0.27
|
—
|
—
|
| Gain On Sale Of Security |
|
2.08
+869.00%
|
-0.27
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-9.89
+38.46%
|
-16.08
-15.94%
|
-13.87
-32.84%
|
-10.44
|
| Net Income From Continuing Operation Net Minority Interest |
|
-9.89
+38.46%
|
-16.08
-15.94%
|
-13.87
-32.84%
|
-10.44
|
| Net Income From Continuing And Discontinued Operation |
|
-9.89
+38.46%
|
-16.08
-15.94%
|
-13.87
-32.84%
|
-10.44
|
| Net Income Continuous Operations |
|
-9.89
+38.46%
|
-16.08
-15.94%
|
-13.87
-32.84%
|
-10.44
|
| Normalized Income |
|
-11.98
+24.22%
|
-15.81
-13.98%
|
-13.87
-32.84%
|
-10.44
|
| Net Income Common Stockholders |
|
-9.89
+38.46%
|
-16.08
-15.94%
|
-13.87
-32.84%
|
-10.44
|
| Diluted EPS |
|
-4.12
+87.75%
|
-33.63
+11.78%
|
-38.12
-22.97%
|
-31.00
|
| Basic EPS |
|
-4.12
+87.75%
|
-33.63
+11.78%
|
-38.12
-22.97%
|
-31.00
|
| Basic Average Shares |
|
2.40
+402.30%
|
0.48
+31.32%
|
0.36
+8.25%
|
0.34
|
| Diluted Average Shares |
|
2.40
+402.30%
|
0.48
+31.32%
|
0.36
+8.25%
|
0.34
|
| Diluted NI Availto Com Stockholders |
|
-9.89
+38.46%
|
-16.08
-15.94%
|
-13.87
-32.84%
|
-10.44
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
3.22
|
| Current Assets |
|
3.04
|
| Cash Cash Equivalents And Short Term Investments |
|
1.05
|
| Cash And Cash Equivalents |
|
1.05
|
| Cash Financial |
|
1.05
|
| Prepaid Assets |
|
1.99
|
| Total Non Current Assets |
|
0.18
|
| Net PPE |
|
0.18
|
| Gross PPE |
|
1.22
|
| Accumulated Depreciation |
|
-1.04
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.18
|
| Other Properties |
|
0.58
|
| Leases |
|
0.46
|
| Total Liabilities Net Minority Interest |
|
2.78
|
| Current Liabilities |
|
1.91
|
| Payables And Accrued Expenses |
|
1.80
|
| Payables |
|
0.46
|
| Accounts Payable |
|
0.46
|
| Current Accrued Expenses |
|
1.35
|
| Current Debt And Capital Lease Obligation |
|
0.10
|
| Current Capital Lease Obligation |
|
0.10
|
| Total Non Current Liabilities Net Minority Interest |
|
0.87
|
| Long Term Debt And Capital Lease Obligation |
|
0.01
|
| Long Term Capital Lease Obligation |
|
0.01
|
| Stockholders Equity |
|
0.44
|
| Common Stock Equity |
|
0.44
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.62
|
| Ordinary Shares Number |
|
0.62
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
108.05
|
| Retained Earnings |
|
-107.61
|
| Total Equity Gross Minority Interest |
|
0.44
|
| Total Capitalization |
|
0.44
|
| Working Capital |
|
1.14
|
| Invested Capital |
|
0.44
|
| Total Debt |
|
0.11
|
| Capital Lease Obligations |
|
0.11
|
| Net Tangible Assets |
|
0.44
|
| Tangible Book Value |
|
0.44
|
| Derivative Product Liabilities |
|
0.86
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-10.57
+8.32%
|
-11.54
+23.62%
|
-15.10
-52.29%
|
-9.92
|
| Cash Flow From Continuing Operating Activities |
|
-10.57
+8.32%
|
-11.54
+23.62%
|
-15.10
-52.29%
|
-9.92
|
| Net Income From Continuing Operations |
|
-9.89
+38.46%
|
-16.08
-15.94%
|
-13.87
-32.84%
|
-10.44
|
| Depreciation Amortization Depletion |
|
0.16
-10.67%
|
0.18
+0.00%
|
0.18
+10.56%
|
0.16
|
| Depreciation |
|
0.16
-10.67%
|
0.18
+0.00%
|
0.18
+10.56%
|
0.16
|
| Depreciation And Amortization |
|
0.16
-10.67%
|
0.18
+0.00%
|
0.18
+10.56%
|
0.16
|
| Stock Based Compensation |
|
0.57
-22.89%
|
0.73
-13.75%
|
0.85
+3.65%
|
0.82
|
| Operating Gains Losses |
|
-2.08
-869.00%
|
0.27
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-2.08
-869.00%
|
0.27
|
—
|
—
|
| Change In Working Capital |
|
0.68
-79.82%
|
3.36
+248.41%
|
-2.26
-393.25%
|
-0.46
|
| Change In Prepaid Assets |
|
-0.44
-114.96%
|
2.96
+196.44%
|
-3.06
-508.53%
|
0.75
|
| Change In Payables And Accrued Expense |
|
1.41
+520.70%
|
0.23
-67.57%
|
0.70
+451.76%
|
-0.20
|
| Change In Other Current Assets |
|
-0.17
-159.79%
|
0.29
+43.72%
|
0.20
+121.75%
|
-0.92
|
| Change In Other Current Liabilities |
|
-0.12
-9.26%
|
-0.11
-9.09%
|
-0.10
-4.21%
|
-0.10
|
| Investing Cash Flow |
|
—
|
0.00
+100.00%
|
-0.02
+70.00%
|
-0.07
|
| Cash Flow From Continuing Investing Activities |
|
—
|
0.00
+100.00%
|
-0.02
+70.00%
|
-0.07
|
| Net PPE Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.02
+70.00%
|
-0.07
|
| Purchase Of PPE |
|
—
|
0.00
+100.00%
|
-0.02
+70.00%
|
-0.07
|
| Capital Expenditure |
|
—
|
—
|
-0.02
+70.00%
|
-0.07
|
| Financing Cash Flow |
|
10.70
+385.52%
|
2.20
+27.05%
|
1.73
-91.33%
|
20.01
|
| Cash Flow From Continuing Financing Activities |
|
10.70
+385.52%
|
2.20
+27.05%
|
1.73
-91.33%
|
20.01
|
| Net Common Stock Issuance |
|
10.70
+537.81%
|
1.68
-3.29%
|
1.73
-89.06%
|
15.85
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.53
|
0.00
-100.00%
|
4.16
|
| Changes In Cash |
|
0.12
+101.30%
|
-9.33
+30.31%
|
-13.39
-233.65%
|
10.02
|
| Beginning Cash Position |
|
1.05
-89.87%
|
10.38
-56.32%
|
23.77
+72.84%
|
13.76
|
| End Cash Position |
|
1.17
+11.50%
|
1.05
-89.87%
|
10.38
-56.32%
|
23.77
|
| Free Cash Flow |
|
-10.57
+8.32%
|
-11.54
+23.73%
|
-15.12
-51.44%
|
-9.99
|
| Common Stock Issuance |
|
10.70
+537.81%
|
1.68
-3.29%
|
1.73
-89.06%
|
15.85
|
| Issuance Of Capital Stock |
|
10.70
+537.81%
|
1.68
-3.29%
|
1.73
-89.06%
|
15.85
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-20 View
- 8-K2026-02-24 View
- 10-Q2026-01-13 View
- 8-K2025-11-14 View
- 8-K2025-10-29 View
- 10-Q2025-08-14 View
- 8-K2025-08-13 View
- 8-K2025-06-24 View
- 10-Q2025-05-15 View
- 8-K2025-05-02 View
- 8-K2025-04-29 View
- 8-K2025-03-28 View
- 8-K2025-03-28 View
- 10-K2025-03-27 View
- 8-K2025-03-19 View
- 8-K2025-03-07 View
- 8-K2025-02-18 View
- 8-K2025-01-10 View
- 8-K2024-12-19 View
- 8-K2024-12-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|